biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce that it has engaged the Anderson Forchung Group LLC (“Anderson Forchung”) of Washington, DC to develop a new SISCAPA Assay to measure the levels of p97 in human blood samples. Anderson Forschung is the developer of SISCAPA Assays, a new proteomics platform that allows accurate quantification and thus subsequent qualification of biomarkers. “We are extremely lucky to not only have an association with Anderson Forschung , but also to have the inventor of the SISCAPA technique and founder of Anderson Forschung, Dr. Leigh Anderson, as a scientific advisor to our Company” says Rob Hutchison, CEO “In addition Dr. Terry Pearson, a director of our Company, is a senior scientific advisor to Anderson Forchung.”.
SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies; see Anderson et al. J Proteome Res. 2004, 3:235-44) is a technique that was developed to measure the levels of proteins in human plasma and is based on immunoaffinity enrichment of peptide surrogates of biomarker proteins and their identification by mass spectrometry. The technique offers several improvements over standard immunoassays: first, the analytes are unambiguously identified by the mass spectrometer; second the assay detects peptide surrogates of the protein targets (rather than the intact proteins) and thus is less subject to variability due to sample degradation; third, SISCAPA is less subject to interference due to autoantibodies that bind the analyte since these antibodies are destroyed during the SISCAPA sample preparation step. SISCAPA will be used as a second, independent method for quantitation of p97 in human plasma in parallel with a sandwich immunoassay, thus adding additional confidence for qualification of p97 as a biomarker for Alzheimer’s disease.
About the Company
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It has extensive and comprehensive intellectual property (“IP”) which it obtained from the University of British Columbia. The Company’s initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer’s disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.
According to the Centers for Disease Control and Prevention (“CDC”), Alzheimer’s disease was listed as the “underlying cause of death” for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.
To find out more about biOasis Technologies Inc. visit www.bioasis.ca.
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”
On Behalf of the Board of Directors
Robin Hutchison, Director and CEO